⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30530659 | 1.00 | — | — | |
| SCHEMBL25364412 | 0.84 | — | — | |
| SCHEMBL29523482 | 0.84 | — | — | |
| SCHEMBL26117628 | 0.72 | PRMT6 (0.32) | — | |
| SCHEMBL25367080 | 0.71 | — | — | |
| SCHEMBL25364821 | 0.68 | NOTUM (0.32) | — | |
| SCHEMBL25364924 | 0.68 | — | — | |
| SCHEMBL26948008 | 0.67 | PDE2A (0.36) | — | |
| SCHEMBL25364111 | 0.67 | CYP2A6 (0.33) | — | |
| Hydrochloric Acid SCHEMBL25366109 | 0.65 | CYP2A6 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |